These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 21795655)

  • 1. Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma.
    de Groot M; Aronica E; Heimans JJ; Reijneveld JC
    Neurology; 2011 Aug; 77(6):532-9. PubMed ID: 21795655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
    Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
    J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam.
    Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H
    Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study.
    Rosati A; Buttolo L; Stefini R; Todeschini A; Cenzato M; Padovani A
    Arch Neurol; 2010 Mar; 67(3):343-6. PubMed ID: 20212232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rare protein sequence variation in SV2A gene does not affect response to levetiracetam.
    Dibbens LM; Hodgson BL; Helbig KL; Oliver KL; Mulley JC; Berkovic SF; Scheffer IE
    Epilepsy Res; 2012 Sep; 101(3):277-9. PubMed ID: 22551666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Mitochondrial Role of SV2a Protein in Aging and Alzheimer's Disease: Studies with Levetiracetam.
    Stockburger C; Miano D; Baeumlisberger M; Pallas T; Arrey TN; Karas M; Friedland K; Müller WE
    J Alzheimers Dis; 2016; 50(1):201-15. PubMed ID: 26639968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation.
    Serajee FJ; Huq AM
    Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.
    de Groot M; Toering ST; Boer K; Spliet WG; Heimans JJ; Aronica E; Reijneveld JC
    Neuro Oncol; 2010 Mar; 12(3):265-73. PubMed ID: 20167814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of levetiracetam on EEG abnormalities in juvenile myoclonic epilepsy.
    Specchio N; Boero G; Michelucci R; Gambardella A; Giallonardo AT; Fattouch J; Di Bonaventura C; de Palo A; Ladogana M; Lamberti P; Vigevano F; La Neve A; Specchio LM
    Epilepsia; 2008 Apr; 49(4):663-9. PubMed ID: 18266754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining modelling and mutagenesis studies of synaptic vesicle protein 2A to identify a series of residues involved in racetam binding.
    Shi J; Anderson D; Lynch BA; Castaigne JG; Foerch P; Lebon F
    Biochem Soc Trans; 2011 Oct; 39(5):1341-7. PubMed ID: 21936812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression patterns of synaptic vesicle protein 2A in focal cortical dysplasia and TSC-cortical tubers.
    Toering ST; Boer K; de Groot M; Troost D; Heimans JJ; Spliet WG; van Rijen PC; Jansen FE; Gorter JA; Reijneveld JC; Aronica E
    Epilepsia; 2009 Jun; 50(6):1409-18. PubMed ID: 19220410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein.
    Gillard M; Chatelain P; Fuks B
    Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation.
    Wang D; Zhou Q; Ren L; Lin Y; Gao L; Du J; Wang Y
    Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levetiracetam monotherapy in children with epilepsy.
    Khurana DS; Kothare SV; Valencia I; Melvin JJ; Legido A
    Pediatr Neurol; 2007 Apr; 36(4):227-30. PubMed ID: 17437904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy.
    Kaminski RM; Matagne A; Leclercq K; Gillard M; Michel P; Kenda B; Talaga P; Klitgaard H
    Neuropharmacology; 2008 Mar; 54(4):715-20. PubMed ID: 18207204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies.
    Rosenfeld WE; Benbadis S; Edrich P; Tassinari CA; Hirsch E
    Epilepsy Res; 2009 Jul; 85(1):72-80. PubMed ID: 19327967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visualization of SV2A conformations in situ by the use of Protein Tomography.
    Lynch BA; Matagne A; Brännström A; von Euler A; Jansson M; Hauzenberger E; Söderhäll JA
    Biochem Biophys Res Commun; 2008 Oct; 375(4):491-5. PubMed ID: 18692481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.